Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
Assessment of Retinal Photoreceptor Outer Segment Length With Optical Coherence Tomography Before and After Light Stimulation - a Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Doreen Schmidl, MD,PhD
- Phone Number: 29810 0043140400
- Email: doreen.schmidl@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Medical University of Vienna, Department of Clinical Pharmacology
-
Contact:
- Doreen Schmidl, MD, PhD
- Phone Number: 29810 0043140400
- Email: doreen.schmidl@meduniwien.ac.at
-
Sub-Investigator:
- Alina Messner, MD
-
Principal Investigator:
- Doreen Schmidl, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- men and women aged over 18 years
- signed informed consent form
- ametropia below 3 diopters
- ability and willingness to follow instructions
for healthy volunteers:
- normal ophthalmologic findings
for primary open angle glaucoma patients (POAG):
- diagnosed POAG
- MD <= 10 dB
for age-related macular degeneration (AMD):
- diagnosed dry AMD
- diagnosed stage II or stage III AMD
Exclusion Criteria:
- Presence of any abnormalities preventing reliable measurements
- Ocular inflammation and ocular disease interfering with the study aims
- Use of photosensitizing medication (phototoxic drugs, photoallergic drugs) in the 3 months preceding the study
- Presence of any condition with the possibility of causing photosensitivity, including systemic lupus erythematosus SLE, Porphyria, Vitiligo, Xeroderma Pigmentosum and Albinism
- Presence of any form of epilepsy
- Ocular surgery in the 3 months preceding the study
- Pregnancy, planned pregnancy or lactating
- Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: healthy volunteers
light stimulation
|
Stimulation of the retina with white light
|
|
Experimental: primary open angle glaucoma patients
light stimulation
|
Stimulation of the retina with white light
|
|
Experimental: age-related macular degeneration patients
light stimulation
|
Stimulation of the retina with white light
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Light stimulation
Time Frame: 1 day
|
Optical path length changes between inner segment outer segment junction and retinal pigment epithelium (RPE) will be measured with OCT in 15 healthy volunteers, 10 POAG patients and 10 AMD patients before and after light stimulation
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Light stimulation of contralateral eye
Time Frame: 1 day
|
Optical path length changes between inner segment outer segment junction and retinal pigment epithelium (RPE) will be measured with OCT in 15 healthy volunteers, 10 POAG patients and 10 AMD patients before and after light stimulation in the contralateral eye
|
1 day
|
|
Difference in photoreceptor layer thickness over the course of 8 hours
Time Frame: 8 hours
|
Influence of circadian rhythm on the length of retinal photoreceptor outer segments
|
8 hours
|
|
En face maps
Time Frame: 1 day
|
test an algorithm for production of en face maps of retinal photoreceptor outer segment length
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Doreen Schmidl, MD,PhD, Department of Clinical Pharmacology, Medical University of Vienna
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OPHT-050418
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.